Rifampin Prophylaxis for Contacts of Haemophilus influenzae Type b Disease
1981; American Medical Association; Volume: 245; Issue: 10 Linguagem: Inglês
10.1001/jama.1981.03310350031018
ISSN1538-3598
AutoresFrederick Cox, Rose C. Trincher, J. P. Rissing, Maurice Patton, George H. McCracken, Dan M. Granoff,
Tópico(s)Bacterial Infections and Vaccines
ResumoRifampin prophylaxis (20 mg/kg once daily for four days) was used in close contacts of children with Haemophilus influenzae type b (HIB) disease. Two hours after a dose, the concentration of rifampin in serum and saliva exceeded the minimum bactericidal concentrations of organisms obtained from four of the carriers. In both a randomized prospective and an open study, nasopharyngeal carriage was eradicated in 37 (95%) of 39 contacts. No cases of serious H influenzae disease occurred in four to six months of follow-up. At the dose and treatment schedule used, rifampin was safe and effective for eradication of HIB carriage. ( JAMA 1981;245:1043-1045)
Referência(s)